000285125 001__ 285125
000285125 005__ 20240229155104.0
000285125 0247_ $$2doi$$a10.1111/cts.13661
000285125 0247_ $$2pmid$$apmid:37920921
000285125 0247_ $$2ISSN$$a1752-8054
000285125 0247_ $$2ISSN$$a1752-8062
000285125 037__ $$aDKFZ-2023-02249
000285125 041__ $$aEnglish
000285125 082__ $$a610
000285125 1001_ $$00000-0001-8036-8806$$aHohmann, Nicolas$$b0
000285125 245__ $$aProtocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
000285125 260__ $$aOxford$$bBlackwell [[-2008]]$$c2023
000285125 3367_ $$2DRIVER$$aarticle
000285125 3367_ $$2DataCite$$aOutput Types/Journal article
000285125 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1703859399_31546
000285125 3367_ $$2BibTeX$$aARTICLE
000285125 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285125 3367_ $$00$$2EndNote$$aJournal Article
000285125 500__ $$aClinical Trial / #EA:A010#LA:A010# / 2023 Dec;16(12):2483-2493
000285125 520__ $$aExpression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation. Inhibition of CYP3A isozymes restores the cells sensitivity to paclitaxel. The combination of gemcitabine and nab-paclitaxel is an established regimen for the treatment of metastasized or locally advanced inoperable pancreatic cancer. Cobicistat is a CYP3A inhibitor developed for the pharmacoenhancement of protease inhibitors. The addition of cobicistat to gemcitabine and nab-paclitaxel may increase the antitumor effect. We will conduct a phase I dose escalation trial with a classical 3 + 3 design to investigate the safety, tolerability, and pharmacokinetics (PKs) of gemcitabine, nab-paclitaxel, and cobicistat. Although the doses of gemcitabine (1000 mg/m2 ) and cobicistat (150 mg) are fixed, three dose levels of nab-paclitaxel (75, 100, and 125 mg/m2 ) will be explored to account for a potential PK drug interaction. After the dose escalation phase, we will set the recommended dose for expansion (RDE) and treat up to nine patients in an expansion part of the trial. The trial is registered under the following identifiers EudraCT-Nr. 2019-001439-29, drks.de: DRKS00029409, and ct.gov: NCT05494866. Overcoming resistance to paclitaxel by CYP3A5 inhibition may lead to an increased efficacy of the gemcitabine and nab-paclitaxel regimen. Safety, efficacy, PK, and RDE data need to be acquired before investigating this combination in a large-scale clinical study.
000285125 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000285125 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285125 7001_ $$0P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aSprick, Martin$$b1$$eFirst author
000285125 7001_ $$aAhmed, Azaz$$b2
000285125 7001_ $$00000-0002-2190-1698$$aBurhenne, Jürgen$$b3
000285125 7001_ $$00000-0003-0294-2483$$aKirchner, Marietta$$b4
000285125 7001_ $$0P:(DE-He78)a49833282b3e64d27fb1d08ceb6b2538$$aLe Cornet, Lucian$$b5$$udkfz
000285125 7001_ $$0P:(DE-He78)ad1537a0b564af5f6cd80581a08a0788$$aKratzmann, Markus$$b6$$udkfz
000285125 7001_ $$aHajda, Jacek$$b7
000285125 7001_ $$00000-0003-1001-103X$$aStenzinger, Albrecht$$b8
000285125 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b9
000285125 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b10
000285125 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b11
000285125 7001_ $$aRiethdorf, Sabine$$b12
000285125 7001_ $$avan Schaik, Ron$$b13
000285125 7001_ $$aPantel, Klaus$$b14
000285125 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens$$b15
000285125 7001_ $$aSeufferlein, Thomas$$b16
000285125 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b17
000285125 7001_ $$00000-0003-0672-6876$$aHaefeli, Walter E$$b18
000285125 7001_ $$0P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aTrumpp, Andreas$$b19$$eLast author
000285125 7001_ $$00000-0003-3843-101X$$aSpringfeld, Christoph$$b20
000285125 773__ $$0PERI:(DE-600)2433157-0$$a10.1111/cts.13661$$gp. cts.13661$$n12$$p2483-2493$$tClinical and translational science$$v16$$x1752-8054$$y2023
000285125 909CO $$ooai:inrepo02.dkfz.de:285125$$pVDB
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a49833282b3e64d27fb1d08ceb6b2538$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad1537a0b564af5f6cd80581a08a0788$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000285125 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000285125 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000285125 9141_ $$y2023
000285125 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCTS-CLIN TRANSL SCI : 2022$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:15Z
000285125 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:15Z
000285125 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-04-16T15:13:15Z
000285125 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000285125 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000285125 9202_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000285125 9201_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000285125 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x1
000285125 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x2
000285125 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x3
000285125 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x4
000285125 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x5
000285125 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x6
000285125 9200_ $$0I:(DE-He78)A010-20160331$$kA010$$lA010 Stammzellen und Krebs$$x0
000285125 980__ $$ajournal
000285125 980__ $$aVDB
000285125 980__ $$aI:(DE-He78)A010-20160331
000285125 980__ $$aI:(DE-He78)W010-20160331
000285125 980__ $$aI:(DE-He78)C110-20160331
000285125 980__ $$aI:(DE-He78)E010-20160331
000285125 980__ $$aI:(DE-He78)ED01-20160331
000285125 980__ $$aI:(DE-He78)D120-20160331
000285125 980__ $$aI:(DE-He78)HD01-20160331
000285125 980__ $$aUNRESTRICTED